Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 35

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 35
---
. While we continue to hold exclusive
licensing rights to the existing patent and unique know-how through Yissum, the eventual expiration of this patent may still limit our
ability to enforce claims specifically related to the CCS lipid composition. To mitigate this risk, the Company intends to pursue next-generation
intellectual property focused on novel antigen combinations, and indication-specific applications (use patents). Nevertheless, there
can be no assurance that these new patent applications will be granted or, if granted, that they will offer commercially meaningful protection.

We may be subject to legal claims against us or claims by us which could have a significant impact on our resulting financial performance.

At any given time, we may be subject to litigation,
the disposition of which may have an adverse effect upon our business, financial condition, or results of operation. Such claims include
but are not limited to and may arise from product liability and related claims if any of the products that we sell is faulty or contain
defects in materials or design. We may be subject to infringement claims from our products. In addition, we may be subject to claims by
our lenders, claims for rent, and claims from our vendors on our accounts payable; and although we have been able to obtain understandings
with the foregoing and have informal forbearance agreements from those parties, one or more of them may elect to commence collection proceedings
which could result in judgments against us and have a significant negative impact on our operations

Currently there are no claims against us from
any third party.

Risks Relating to our Operations in Israel

Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including Israel’s multi-front war with terrorist groups in neigh boring countries, such as Hezbollah in Lebanon and Hamas in the Gaza Strip, and state actors such as Iran, and Israel’s response thereto

A significant portion of our R&D operations
is based in Israel. Recent escalations in regional conflicts have disrupted business activities and may continue to do so. We have developed
contingency plans, including the potential outsourcing of critical operations and establishing remote work protocols for key personnel.
However, prolonged disruptions could materially impact our ability to meet development milestones. Our technology development headquarters,
which houses substantially all of our research and development team, including researchers, and clinical and regulatory personnel are
located at our headquarters in Herzliya, Israel. Three employees are currently engaged